Kyle Munz

Results from a phase 1b trial demonstrate promise for a novel treatment developed to address the needs of patients with narcolepsy type 2 (N2) and idiopathic hypersomnia (IH). Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of […]

Electronic cigarettes (also called e-cigarettes or vapes) were introduced in the US in the mid-2000s and grew increasingly popular with the advent of flavored products, such as Juul in 2015. Prior to these entering the market, vape usage in youths

Today, Protega Pharmaceuticals announced that the FDA granted approval for oxycodone hydrochloride (RoxyBond) as an alternative treatment for managing severe pain. The approval has been granted for the use of immediate-release (IR) schedule II tablet at a dose of 10

More accurate identification of self-injurious thoughts and behaviors (SITB) could ensure more equitable care in efforts to prevent youth suicide. According to a study published today in JAMA Network Open, chief concerns and diagnostic codes have done a disservice to

A mastectomy is a common procedure that involves the removal of all breast tissue as a treatment for breast cancer. For individuals who are considered high-risk for developing breast cancer, an elective mastectomy, also termed a prophylactic or risk-reducing mastectomy,

Back in 2019, the World Health Organization (WHO) deemed vaccine hesitancy—the outright refusal or reluctance to get vaccinated regardless of the availability of vaccines—as a top-10 threat to global health.1 At the time, WHO estimated that vaccinations prevented up to

Viet Le, PA-C, Intermountain Health, shares his expertise with cardio-renal-metabolic models. Implementing these care models comes with its own set of challenges, which reinforces the need for effective communication and collaboration, Le explains. Cardio-renal-metabolic models, care barriers, the role of

Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, explores the topic of risk stratification in chronic kidney disease (CKD), innovations in this area, and how the interplay of population health strategies and policy reformation can benefit patient care. With the

For patients with opioid use disorder (OUD), receiving methadone (Methadose, Dolophine) was associated with a lower risk of treatment discontinuation vs buprenorphine (Cizdol, Brixadi)/naloxone (Narcan). These findings are based off of a new comparative analysis published today in JAMA Network.1

Seth Southwick, MHA, of Intermountain Health, overviews the Intermountain Health Kidney Services model amid Intermountain’s quest to improve patient outcomes. The model involves a variety of techniques, particularly by leveraging community organizations and leaning into advanced analytics and machine learning